The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.
Dana E. Rathkopf
No relevant relationships to disclose
Daniel Costin Danila
No relevant relationships to disclose
Michael J. Morris
No relevant relationships to disclose
Susan F. Slovin
No relevant relationships to disclose
Jill Elise Steinbrecher
No relevant relationships to disclose
Gabrielle Arauz
No relevant relationships to disclose
Peter J. Rix
Employment or Leadership Position - Aragon Pharmaceuticals
Stock Ownership - Aragon Pharmaceuticals
Edna Chow Maneval
Employment or Leadership Position - Aragon Pharmaceuticals
Stock Ownership - Aragon Pharmaceuticals
Isan Chen
Employment or Leadership Position - Aragon Pharmaceuticals
Stock Ownership - Aragon Pharmaceuticals
Josef J. Fox
No relevant relationships to disclose
Martin Fleisher
No relevant relationships to disclose
Steven M. Larson
No relevant relationships to disclose
Howard I. Scher
No relevant relationships to disclose